Economic, regulatory, and practice issues in molecular pathology and diagnostics

American Journal of Clinical Pathology

Volumn 112, Issue 1 SUPPL. 1, 1999, Pages

  Ross, Jeffrey S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Benefits; Cost; Molecular diagnostics

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; HORMONE; HORMONE RECEPTOR; TRASTUZUMAB;

BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; CLINICAL LABORATORY; CLINICAL PRACTICE; COLORECTAL CANCER; DIAGNOSTIC PROCEDURE; ECONOMIC ASPECT; GENETIC PREDISPOSITION; HEALTH CARE COST; HUMAN; INFECTION; MANAGED CARE; MOLECULAR BIOLOGY; PHARMACOGENOMICS; PRIORITY JOURNAL; PROSTATE CANCER; REIMBURSEMENT; REVIEW; UTERINE CERVIX DYSPLASIA; VIRUS LOAD;

COMMUNICABLE DISEASES; GENETIC SCREENING; GENETIC TECHNIQUES; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MANAGED CARE PROGRAMS; NEOPLASMS; PATHOLOGY, CLINICAL;

EID: 0033499854     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Ferreira-Gonzalez A, Garrett CG. Pitfalls in establishing a molecular diagnostic laboratory. Human Pathol. 1996;27:437-440.
2. Watson MS. Current activities involving economic, regulatory, and practice issues in molecular genetic testing. Diagn Mol Pathol. 1995;4:233-234.
3. Ross JS. Molecular pathology and managed care: challenges and opportunities. Diagn Mol Pathol. 1998;10:1-3.
4. van der Riet AA, van Hout VA, Rutten FF. Cost effectiveness of DNA diagnosis for four monogenic diseases. J Med Genet. 1997;34:741-745.
5. Bombard AT, Fields AL, Aufox S, et al. The genetics of ovarian cancer: an assessment of current screening protocols and recommendations for counseling families at risk. Clin Obstet Gynecol. 1996;39:860-872.
6. Rose DN, Sacks HS. Cost-effectiveness of cytomegalovirus disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing. AIDS. 1997;11:883-887.
7. Paavonen J, Puolakkainen P, Paukku M, et al. Cost-benefit analysis of first-void urine Chlamydia trachomatis screening program. Obstet Gynecol 1998;92:292-298.
8. Howell MR, Quinn TC, Brathwaite W, et al. Screening women for Chlamydia trachomatis in family planning clinics: the cost-effectiveness of DNA amplification assays. Sex Transmit Dis. 1998;25:108-117.
9. Vasen HF, van Ballegooijen M, Buskens E, et al. A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer. 1998;82:1632-1637.
10. van Ballegooijen M, van den Akker-van Marle ME, Warmerdam PG, et al. Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the cost-effectiveness. Br J Cancer. 1997:76:651-657.
11. Apple SK, Hecht JR, Novak JM, et al. Polymerase chain reaction-based mutation detection of pancreatic adenocarcinoma in routine cytology smears. Am J Clin Pathol. 1996;105:321-326.
12. Akao T, Kahei Y, Wu XX, et al. Semi-quantitative analysis of telomerase activity of exfoliated cells in urine of patients with urothelial cancers. Urol Oncol. 1997;3:118-124.
13. Sidransky D. Nucleic acid-based methods for the detection of cancer. Science. 1997;278:1054-1059.
14. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist. 1998;3:237-252.